BJMO - volume 12, issue 7, november 2018
A. Awada MD, PhD, J-F. Baurain MD, PhD, P. Clement MD, PhD, P. Hainaut MD, S. Holbrechts MD, PhD, K. Jochmans MD, V. Mathieux MD, J. Mebis MD, M. Strijbos MD, PhD, C. Vulsteke MD, PhD, T. Vanassche MD, P. Verhamme MD
Unprovoked venous thromboembolism (VTE) may be the earliest sign of malignancy, and as a result, screening for occult cancer in these patients has become routine practice. However, the elaborateness of this screening is subject to debate and varies between medical centres. This study’s expert panel, consisting of oncologists and thrombosis specialists, aimed to develop a practical Belgian guidance for adequate cancer screening in patients with unprovoked VTE. In summary, comprehensive non-invasive cancer screening consisting of a medical history assessment, physical examinations, basic blood tests and a chest X-ray is sufficient to pick up the vast majority of occult cancers. When specific abnormalities are picked up by the battery of tests in the comprehensive non-invasive cancer screening, more extensive screening using CT scans are recommended. Routine CT screening in all patients presenting with an unprovoked VTE does not provide a significant clinical benefit and should not be routinely performed. In the presence of specific risk factors (e.g., older age, smoking history, previous VTE), physicians are advised to be more vigilant. Finally, given the significant anxiety that cancer screening may cause to patients, accurate and clear patient communication is key. A complete list of guidance statements is provided at the end of the article.
(BELG J MED ONCOL 2018;12(7):326–329)
Read moreBJMO - volume 12, issue 2, march 2018
W. Lybaert MD, P. Clement MD, PhD, K. Punie MD, J. Mebis MD, M. Renard MD, H. Wildiers MD, PhD
Chemotherapy-induced nausea and vomiting remains an important adverse effect of treatment in daily clinical practice. Recently, new data on combinations of antiemetic agents became available for the prevention of acute and delayed nausea/vomiting in patients receiving highly and moderately emetogenic chemotherapy. As a result, the leading international cancer societies updated their antiemesis guidelines. This text aims at providing guidance regarding these new regimens in the prophylaxis of chemotherapy-induced nausea and vomiting, with a particular focus on highly emetogenic chemotherapy.
(BELG J MED ONCOL 2018;12(2):51–60)
Read moreBJMO - volume 12, issue 3, february 2018
J. Robijns PhD, S. Censabella , S. Claes , Luc Pannekoeke , Lore Bussé , D. Colson , Iris Kaminski , A. Maes MD, P. Bulens MD, M. Brosens , L. Noé MD, Ivo Lambrichts , A. Timmermans , V. Somers , J. Mebis MD
BJMO - volume 12, issue 3, february 2018
J. Mebis MD, S. Censabella , S. Engels , Guy Orye , S. Marquette MD, C. Van Narsenille , L. Vansteelant MD, L. Noé MD, A. Maes MD, P. Bulens MD, D. Luyten MD, E. Joosens MD
BJMO - volume 12, issue 3, february 2018
T. Wessels MD, J. Mebis MD
BJMO - volume 12, issue 3, february 2018
J. Mebis MD, S. Censabella , S. Engels , C. Van Narsenille , Guy Orye , S. Marquette MD, L. Vansteelant MD, L. Noé MD, A. Maes MD, P. Bulens MD, D. Luyten MD, E. Joosens MD
BJMO - volume 11, issue 8, december 2017
J. Robijns PhD, S. Censabella , P. Bulens MD, A. Maes MD, L. Noé MD, M. Brosens , L. Van den Bergh MD, PhD, S. Claes , J. Mebis MD
Photobiomodulation therapy is based on the application of visible and/or (near-)infrared light on the target tissue. We performed a review of 34 articles on the use of photobiomodulation therapy in the management of cancer related lymphoedema, oral mucositis, radiodermatitis, chemotherapy-induced peripheral neuropathy, osteonecrosis of the jaw, and xerostomia/hyposalivation. The findings suggest that photobiomodulation therapy is a promising option for the management of these cancer therapy-related side effects.
(BELG J MED ONCOL 2017;11(8):364–374)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
